PDCD1 and melanoma: Jiang et al., showed that gene signatures related to T cell dysfunction and exclusion from the TME can predict a therapy response to immune checkpoint inhibitors, anti-PD-1 and anti-CTLA4 mAbs, in melanoma patients [29].